Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

om normal to high at any time was 11.9 percent.

At the time of the interim analysis of HGKB, 23 PDSS events were reported in 22 patients. Between 30 September, 2007 and 31 May, 2008, four additional events have been reported in this ongoing trial.

About Long-acting Injectable Antipsychotic Medications

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines state that poor or partial treatment compliance is a major problem in the long-term treatment of schizophrenia. Depot formulations should be considered as a treatment option when a patient expresses a preference for such treatment due to convenience or if it is determined that a depot formulation is necessary to help avoid nonadherence to oral medications.(i)

Long-acting antipsychotic formulations have been associated with improved treatment adherence and reduced treatment failures.(ii) By administering long-acting medications, healthcare professionals know when patients have received their medication and can immediately detect non-adherence when a patient fails to return for a scheduled injection.(iii) Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics allow for stable concentrations of the active drug to remain at a therapeutic range for an extended period of time.(iv)

About Schizophrenia

Schizophrenia is a severe and debilitating illness with symptoms such as delusions (false beliefs that cannot be corrected by reason), hallucinations (usually in the form of non-existent voices or visions), disorganized speech and severe disorganized or catatonic behavior. These signs and symptoms are associated with marked social or occupational dysfunction. Features of schizophrenia consist of characteristic signs and symptoms that have been present for a significant portion of time during a one-month period, with some signs of the disorder persisting for at least six months.(v) In addition to these symptom
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)..., CHICAGO, Nov. 29 At the 95th S...logical Society of North America (RSNA), "Images, ...hcare booth (#825) from November 29 to December 3 ...side Center, Hall D) in Chicago. This year,s booth...f Siemens support for its customers to generate, p...
(Date:11/29/2009)..., CHICAGO, Nov. 29 FUJIFILM Medi...eld Digital Mammography (FFDM) with over 7,000 ins...M system for the first time in the US. The Aspire...ous selenium (a-Se) next generation detector techn... noise and higher spatial resolution at a reduced ...
(Date:11/28/2009)..., CHICAGO, Nov. 28 Siemens Healt... of its Tim ® (Total imaging matrix) technol...ghput) engine. Both technologies are introduced in...the new MAGNETOM Skyra* 3T scanners at the 95th Sc...ogical Society of North America (RSNA) from Novemb...
Breaking Medicine Technology:Siemens Delivers Images per the Customer's Request - 'Images My Way' 2Siemens Delivers Images per the Customer's Request - 'Images My Way' 3Siemens Delivers Images per the Customer's Request - 'Images My Way' 4Siemens Delivers Images per the Customer's Request - 'Images My Way' 5Siemens Delivers Images per the Customer's Request - 'Images My Way' 6Siemens Delivers Images per the Customer's Request - 'Images My Way' 7Siemens Delivers Images per the Customer's Request - 'Images My Way' 8Siemens Delivers Images per the Customer's Request - 'Images My Way' 9FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 2FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 3FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 4Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 74 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 14 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 24 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 34 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 44 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 54 out of 5 CA Voters Demand Health Insurer 22Code of Conduct 22 50690 6Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of Abortion Pill 50687 1Ohio Supreme Court Strikes a Blow to Planned Parenthood in Upholding Regulation of Abortion Pill 50687 2Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 1Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 2Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 50684 3
...tCall/ --,Medivation, Inc. today announced that it...ime on Monday, June 11, to discuss top-line,12-mon...ebo-controlled Phase 2 clinical trial of Dimebon(T...ease. , Rachelle Doody, M.D., Ph.D., lead investig...lts for the first time at a,scientific meeting at ...
...al results from a,Phase II study presented for the... annual meeting showed that MK-0974, an,investigat...receptor antagonist, significantly improved migrai...placebo, and the relief was,sustained through 24 h...study. Responses specific to other measures, such ...
Other Medicine Technology:Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study 2Medivation to Host Conference Call to Discuss Top-Line 12-Month,Results From Dimebon Alzheimer's Disease Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:11/28/2009)...nsider change after 30-minute psychosocial interve...HealthDay News) -- A program that gets persistent ...ir dangerous behavior may lead to significant and ... The new study included 184 men and women with two...ere randomly assigned to one of two interventions....
(Date:11/27/2009)...Replikins Ltd. today issued its latest biochemical...s that the lethality of the virus has dropped from...rent outbreak in the spring of 2009 to resting non...H1N1 infectivity count, however, remains increased...er 27, 2009 -- Biotech firm Replikins Ltd., which ...
(Date:11/27/2009)... 27 Shamir Optical Indus...provider of innovative products and technology to ...ts board of directors had declared a dividend dist...(approximately NIS 37.62 million based on the Nove... approximately US$ 0.609 (approximately NIS 2.3 ba...
(Date:11/27/2009)...™ announced today that Spectrum Health (Gran...erprise orthopedic templating solution and its Tra... (PRWEB) November 27, 2009 -- Voyant Heal...and Rapids, Michigan) has licensed its TraumaCad E...raumaCad Extend workflow solution, to allow its or...
(Date:11/26/2009)... The diabetes population in the Uni...rs and annual medical spending on the disease is p... today, according to a study published in the Dece...ging Diabetes ® Program (NCDP), a program of ...from the University of Chicago. ,, According to...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4
...ng to the parliament's Health Select Committee the...England needs to be reviewed//. It pointed out...entistry and eye care do not have any comprehensib...t on the patients and the evidence for this fact i...
...eturning from malaria-prone Garo Hills region, Meg...alised with symptoms of the same disease. // ...ay, was admitted to the civil hospital here with m...ict town Tura. Malaria had claimed 40 lives i...
...o Kills/Smoking Kills" -- such health warnings wou...ng which the sellers would attract stringent penal...arnings that could appear on tobacco packages incl...ry headed by Anbumani Ramadoss, who has been a sta...
...ot uncommon to have testimonies of surgeries - ins... patients' bodies, a stark reminder of medical// n...s and even death of unfortunate patients. Statisti...named as the 'magic wand' which will ensure surgeo...
...ot healthy to lose weight soon after giving birth,... being advised about the pitfalls of following cel...gure soon after child birth, which can have seriou...trition levels in both the mother and the baby. A ...
...ury University researcher Dr Victoria Metcalf is o...rs about fish. Metcalf will use the genetic filter...bolize fat. This study will aid in the understandi...ans who get the energy from carbohydrates. In her ...
Other Medicine News:
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: